摘要
嵌合抗原受体(CAR)-T细胞免疫治疗难治/复发急性淋巴细胞白血病(R/R ALL)是血液系统恶性疾病治疗领域的突破性进展之一。然而,该领域还存在异基因CAR-T细胞免疫排斥、白血病复发、能否将CAR-T细胞用于微小残留病(MRD)阳性患者的干预和初诊ALL患者的治疗等诸多挑战,只有建立针对上述挑战的相应策略才能进一步提高CAR-T细胞免疫治疗ALL的安全性、有效性,改善临床预后。
Chimeric antigen receptor(CAR)-T cell immunotherapy for refractory and relapsed acute lymphoblastic leukemia(R/R ALL)is one of the breakthroughs in the field of hematological malignant disease treatment.However,several challenges remain,such as immune rejection of allogeneic CAR-T cells,leukemia relapse,as well as could we apply CAR-T cell immunotherapy to ALL patients with positive measurable residual disease and those of newly diagnosed cases.The safety and efficiency of CAR-T therapy will be further improved for patients with ALL only by establishing appropriate strategies to address these challenges.
作者
常英军
赵翔宇
Chang Yingjun;Zhao Xiangyu(Peking University People′s Hospital&Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China)
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2022年第8期777-782,共6页
Chinese Journal of Laboratory Medicine
基金
京津冀协同创新推动项目(Z18111000960000)
首都卫生发展科研专项(首发2018-2-4084)。
关键词
免疫疗法
过继
嵌合抗原受体T细胞
难治/复发急性淋巴细胞白血病
复发
免疫排斥
微小残留病
Immunotherapy,adoptive
Chimeric antigen receptor T cell
Refractory and relapsed acute lymphoblastic leukemia
Leukemia relapse
Immune rejection
Measurable residual disease
